From Walgreens Offshoot to Infusion Giant: The Option Care Health Story
An Amazon-like moat—at just 15x earnings.
“We have the largest footprint of compounding pharmacies across the United States. We have 92 pharmacies, and we have access to virtually the entire U.S. population. Consequently—no surprise—we also have the broadest array of therapies partnering with pharma, and we're the only national provider that's in-network with every major payer across the United States.” —Michael H. Shapiro, Executive VP & CFO @ Bank of America Securities 2024 Leveraged Finance Conference
The Shift to Home and Alternate Site Infusion
Home and alternate site infusion is becoming one of the most important parts of healthcare. These services involve delivering complex medications through an IV outside of a hospital—either at a dedicated infusion center or directly in a patient’s home with a visiting nurse. Compared to traditional hospital care, this approach is far more convenient for patients, significantly less expensive, and often safer, as hospitals carry higher risks of infection. It’s no surprise that insurance companies, hospitals, and patients all increasingly prefer this model. As demand for specialized treatments continues to rise, shifting care out of hospitals provides the healthcare system with a clear way to reduce costs while improving patient outcomes. This represents a transformative secular tailwind that is just starting to accelerate.
A Fragmented Landscape—and a Clear Leader
Despite its growing importance, the alternative care space remains largely fragmented, with few players truly focused or capable of consolidating and emerging as dominant. Several providers have already exited this complex segment due to its inherent challenges, yet one company is quietly emerging as a clear leader.
Enter Option Care Health.
Corporate History
Option Care Health’s modern history began in April 2015, when Madison Dearborn Partners (MDP) acquired Walgreens Infusion Services through its investment vehicles, HC Group Holdings I & II. The business was rebranded as Option Care, with MDP as the majority owner while Walgreens retained a significant stake.
John Rademacher joined as COO in 2015 and became CEO in 2017. Michael Shapiro became CFO in 2015.
In August 2019, Option Care completed a reverse merger with BioScrip, Inc., a publicly traded infusion and home care provider, and was renamed Option Care Health, Inc., with Rademacher as CEO and Shapiro as CFO.
From 2021 to 2023, MDP and Walgreens fully divested their stakes through secondary offerings. By June 2023, MDP’s investment vehicle, HC I, no longer held any shares.
Investment Thesis
Option Care Health (OPCH) is the clear national leader in providing infusion treatments outside of hospitals. Infusions deliver medications directly into a patient’s bloodstream—often for infections, immune disorders, or cancer. Traditionally requiring a hospital stay, these treatments are now administered at OPCH’s infusion centers or directly in patients’ homes via mobile nurses.
This shift from high-cost hospital care to lower-cost outpatient and home settings is one of the strongest growth trends in healthcare today. Insurance companies and hospitals increasingly rely on OPCH to enable this transition, making the company an essential partner with advantages that are extremely difficult for competitors to replicate.
Efficient Infrastructure
OPCH has built the nation’s leading alternate site infusion platform, with 91 pharmacies (77 co-located with ambulatory infusion suites) and 99 stand-alone infusion suites, reaching 96% of the U.S. population. Infusions through OPCH cost 20–40% less than hospital outpatient departments (HOPDs), making it the natural discharge partner for hospitals operating under bundled DRG payment models. This infrastructure is supported by over 5,000 clinicians and an integrated nursing network, reinforced by acquisitions like Naven Health.
Expanding Payer and Hospital Relationships
With its infrastructure in place, OPCH is the preferred partner for payers and hospitals seeking to reduce costs and improve outcomes. The company holds over 1,400 contracts across 800 relationships, including all top 10 national payers. As payers drive site-of-care optimization initiatives and hospitals seek seamless discharge pathways, referral volume continues to grow—driving utilization, market share gains, and fixed-cost leverage.
Reinvestment into High-Value Services
Growing scale and profitability enable OPCH to reinvest into its platform to widen its moat further. The rollout of its Advanced Practitioner Model allows nurse practitioners to manage increasingly complex therapies previously confined to hospitals or specialist offices, expanding OPCH’s reach into oncology, neurology, and rare diseases. Its therapy base—75% chronic, 25% acute—combined with a product profit mix driven largely by generics and biosimilars, provides stability amid drug pricing shifts while deepening its value to payers, hospitals, and pharmaceutical partners.
The above points act as a virtuous cycle, reinforcing the company’s position. OPCH’s efficient infrastructure attracts more referrals, which generates higher volumes and revenue. That revenue is reinvested into services and technology that further strengthen its infrastructure. This self-reinforcing flywheel positions Option Care Health as an indispensable platform in modern healthcare—cost-efficient, clinically capable, and increasingly impossible to displace.
Why This Opportunity Exists
Healthcare remains a complex, highly regulated industry, often viewed with caution by investors. Dependence on managed care organizations and third-party payers can create pricing pressures and reimbursement delays. Broader concerns include evolving drug reference pricing—such as upcoming provisions under the Inflation Reduction Act (IRA) granting Medicare negotiation authority—supply chain vulnerabilities, labor shortages, cybersecurity risks, and intense competition from vertically integrated models aiming to capture a greater share of patient spending.
Acute care, in particular, is typically considered an unattractive business segment due to its operational complexity and high turnover. As a result, many investors overlook companies with significant acute care exposure.
Insider Ownership and Alignment
John C. Rademacher (President and CEO)John Rademacher has served as CEO since 2017, after joining as COO in 2015, and has been on the board since 2019. His 2024 base salary was $1,000,000, but his equity exposure far exceeds this. He beneficially owns approximately 621,000 shares, including exercisable stock options, and holds an additional ~110,000 unearned Performance Stock Units (PSUs), bringing his total potential equity interest to ~731,000 shares, worth roughly $22.7 million at a $31 share price.
Michael Shapiro (Chief Financial Officer)Michael Shapiro has been CFO since 2015. His 2024 base salary was $612,000, but like Rademacher, his real exposure is in equity. He beneficially owns approximately 207,000 shares, including exercisable options, and holds an additional ~18,000 unearned PSUs, bringing his total potential equity interest to ~225,000 shares, worth around $7.0 million.
It’s clear that Option Care Health’s compensation structure is heavily weighted toward performance-based equity. Leadership is deeply invested alongside shareholders—and everyone’s incentives are aligned.
Option Care Health Operations
At its core, OPCH operates as the largest independent provider of home and alternate site infusion services in the United States. Rather than requiring patients to endure lengthy and costly hospital stays, OPCH partners with hospitals, insurers, and pharmaceutical companies to deliver complex intravenous therapies safely, efficiently, and at lower cost.
OPCH’s operations are built upon two pillars:
A national footprint of specialized pharmacies, infusion suites, and an integrated clinical workforce—enabling it to prepare and administer a broad array of therapies with unmatched reach, consistency, and patient experience.
Deep partnerships with hospitals, payers, pharmaceutical manufacturers, and patients themselves—positioning OPCH as an indispensable partner within the broader healthcare system to reduce costs, improve outcomes, and expand access to care.
To paraphrase the famous Jeff Bezos quote on Amazon’s strategy: it’s hard to imagine a future where consumers want higher prices and slower delivery. It’s equally hard to imagine a future where OPCH’s customers—whether patients, hospitals, or insurers—want care that is less convenient, more expensive, and less safe.
Sweat Equity
OPCH provides an extensive range of infusion therapies for both acute and chronic conditions—from anti-infectives that keep patients out of the hospital, to immunoglobulin therapies, nutrition support, bleeding disorder treatments, and even specialized women’s health programs.
Management sees acute therapies, which make up roughly 25–27% of revenue, as strategically important: profitable, generic-based services that strengthen referral relationships with hospitals and payers.
While many investors view acute infusion therapies as operationally complex and unappealing, OPCH uses them as a strategic wedge. Over the past year, major competitors like Coram and United have exited certain acute services, and as recently as late 2024, another large infusion provider announced its intention to exit parts of the acute market entirely. Why? Acute therapies are intense, high-touch, and operationally demanding, with patients often requiring treatment for only two weeks to two months. For diversified healthcare giants, the capital expenditures and operational complexity simply aren’t worth the effort. But for OPCH, these challenges create a competitive moat.
By offering both acute and chronic therapies, OPCH positions itself as a one-stop solution for hospitals, payers, and referral partners—who are more likely to use OPCH than a provider that offers only one or the other.
As CFO Michael Shapiro explains, “The breadth of our portfolio and having both acute and chronic therapies creates a competitive advantage for us.”
If acute therapies are OPCH’s strategic wedge, chronic therapies are its foundation for stable, long-term earnings. Chronic therapies make up roughly 75% of OPCH’s revenue. While gross margins on chronic therapies (10–25%) are lower than those on acute therapies (often 50%+), the absolute gross profit dollars per patient are far higher. Why? Because these patients require treatment not just for weeks, but for years—sometimes for life.
This creates predictable, recurring revenue streams—exactly what payers, investors, and OPCH itself value most.
Importantly, while roughly half of chronic therapy revenue comes from branded drugs, three-quarters of OPCH’s product profit is driven by generics and biosimilars. Management describes these as far more stable, with “much less volatility and variability in reference prices” compared to branded drugs.
This discrepancy creates a hidden advantage: despite appearing heavily exposed to branded drug pricing dynamics, the reality is that OPCH’s profit engine is anchored by stable, efficiently priced therapies with far less volatility. In an industry often plagued by reimbursement swings and pricing shocks, finding a healthcare business with this level of embedded stability is rare.
Growth Mode: Layering Services onto Fixed Infrastructure
Option Care Health is uniquely positioned to scale in a capital-light way. With its national footprint already in place—reaching over 96% of the U.S. population through its pharmacies, infusion suites, and mobile nursing network—future growth doesn’t require building more facilities. It simply means expanding the services offered across the infrastructure they’ve already built.
The most exciting example of this strategy is the Advanced Practitioner (AP) model, which places nurse practitioners directly within OPCH’s infusion suites alongside registered nurses. This initiative enables OPCH to manage more complex infusion therapies—in fields like oncology, neurology, and rare diseases—that would traditionally be confined to a hospital setting.
As CEO John Rademacher noted on the Q4 2024 earnings call: “We believe the advanced practitioner clinical model is highly complementary to our network of compounding pharmacies, and we intend to continue enhancing and expanding our infusion site network to incorporate broader clinical capabilities… The expansion of our advanced practitioner model remains a priority in 2025 and beyond.”
The AP model effectively raises the clinical ceiling for what can be treated in an alternate site setting. Today, the complexity of therapies OPCH can deliver is limited by the scope of practice for registered nurses. By rolling out nurse practitioners systemwide, OPCH unlocks a broader array of services—increasing acuity, duration, and reimbursement—all while deploying minimal incremental capital.
This expansion does more than just increase revenue. It further entrenches OPCH’s moat and strengthens its flywheel: more services lead to more referrals, deeper relationships with payers and providers, and greater utility to pharmaceutical partners who need sophisticated delivery infrastructure for their therapies. The infusion suite becomes the clinical home for a growing portfolio of care.
Crucially, this is not theoretical upside. Management has already made clear that:
The AP model is being piloted at a limited number of sites, but performance has been strong.
Only ~50% of OPCH’s total infusion suite capacity is currently utilized, meaning the physical infrastructure is already in place to absorb significant growth without meaningful expansion capex.
Shifting more volume into alternate site settings (versus home visits) saves on costly “windshield time” and improves labor efficiency—yet another margin lever that scales with utilization.
When contemplating the long-term trajectory of this growth, I’m reminded of what Warren Buffett describes as the ideal business: one that can grow large without needing heavy incremental capital. Option Care Health already has the infrastructure—the pharmacies, infusion suites, payer contracts, and clinical workforce. Now, it’s simply layering higher-value services onto that foundation—creating a path for high-return, capital-light growth that amplifies the value of what’s already been built.
In essence, Option Care is transitioning from infrastructure builder to infrastructure leverager. And the AP model is just the beginning.
Valuation
With 163.7 million shares outstanding and a share price of $30.84, Option Care Health currently trades at a market cap of $5.05 billion. After accounting for $930 million in net debt, the enterprise value stands at $5.98 billion. Based on management’s most recent 2025 guidance, EBITDA is expected to be approximately $462.5 million. After backing out $40 million in stock-based compensation and an estimated $35 million in maintenance capex, we’re left with about $387.5 million in owner earnings—putting OPCH at roughly 15.4x 2025 owner earnings, an undemanding multiple for a capital-light compounder with an entrenched moat.
Management has been refreshingly consistent in their articulation of the long-term growth algorithm. CFO Michael Shapiro often describes OPCH as a “high single-digit top-line, low double-digit EBITDA growth enterprise,” with EPS growing even faster due to ongoing share repurchases. Shapiro reinforced this at the 2025 Bank of America Healthcare Conference: “We like to say EBITDA doesn’t pay the light bill—cash does. And last year, we generated more than $0.25 billion in free cash.”
That discipline continues in 2025, where OPCH is guiding to at least $320 million in operating cash flow and more than $250 million in free cash flow after capex. The message is clear: this is a business that turns EBITDA into real, deployable capital.
Over the past five years, they’ve grown revenue at a 12% CAGR and doubled EBITDA growth relative to top-line gains. Looking forward, even modest assumptions paint a compelling picture. If owner earnings grow at 11% annually—consistent with the low end of management’s guidance and below historical performance—they could reach $653 million in five years.
If Option Care continues its recent pace of $250 million in annual share repurchases at an average buyback price of $38, the share count would decline from 163.7 million to approximately 130.8 million. Assuming net debt remains stable at $930 million, enterprise value in year five would be $10.06 billion (15.4 × $653 million), translating to an equity value of $9.13 billion. Divide that by the reduced share count, and you arrive at a stock price of $69.80—a 126% gain from today’s $30.84 price.
That equates to a 17.4% compound annual return—with no help from multiple expansion, margin uplift, or major acquisitions. It’s just steady, proven execution of a business plan that management has already communicated and consistently outperformed.
This kind of setup feels increasingly rare: a capital-efficient business with an already-built infrastructure, clear embedded growth levers, and a management team with a long track record of delivering. The moat is real, the flywheel is turning, and the capital-light nature of the model means that each incremental dollar of earnings goes further. If anything, the valuation today likely understates the quality and predictability of the business. For a company growing at this pace, with this level of return on reinvested capital, a 15x multiple may someday look conservative.
Nice writeup. Did you do any market sizing work? Curious as to how big the opportunity is and how much they've captured as of now.